INTRODUCTION {#s1}
============

Response to tyrosine kinase inhibitors (TKI) is usually monitored by measurement of hematologic, cytogenetic, and molecular responses \[[@R1], [@R2]\]. BCR-ABL mRNA transcripts are the major parameter used to assess the TKI molecular response and are usually measured in the peripheral blood at diagnosis, every 3 months until BCR-ABL transcripts are \<0.1%, and then every 3-6 months thereafter \[[@R3]\]. According to the National Comprehensive Cancer Network (NCCN), Imatinib therapy is working if BCR-ABL transcripts are ≤10% after 3 months, \<1% after 6 months, or undetectable after 18 months of therapy.

However, TKI-treated patients in which the BCR-ABL gene is no longer found or is un-detacted copies do not seem to be cured. In most of the cases, either the CML moves towards to the advanced phase, or BCR-ABL and CML cells show remission in more than half of the people who cease TKI treatment \[[@R4], [@R5]\].

Hence, genome-wide profiling of different phases of Imatinib-treated CML is expected to uncover signaling pathways and molecular mechanisms involved in Imatinib treatment at different phases of CML. Recent studies have suggested that clonal Copy Number Aberrations (CNAs) are rare or even absent in pediatric/adult-CML-chronic phase (CML-CP) and are relatively common at progressed stages \[[@R7], [@R12]--[@R14]\]. At the transcript level, signature genes identified in whole blood and leukemic stem cells have been shown to distinguish chronic phase (CP) from blast crisis (BC) \[[@R6]\] and to predict major cytogenetic response and non-response in chronic-phase CML patients treated with Imatinib \[[@R7]\]. However, an *in vitro* study and found no alteration in genomic changes of bone marrow-derived HSCs and HPCs from CML patients on Imatinib treatment \[[@R8]\].

Activation of ERK/MAPK, JAK-STAT, ErbB, cell surface genes, genes of oxidative metabolism and DNA repair pathways, activation of inflammatory cytokines and dysregulation of key cancer signaling pathways, as well as down-regulation of pro-differentiation and TGF-β/BMP signaling pathways have also been responsible for proliferation in CML \[[@R8]--[@R10]\].

In addition to copy number variations (CNVs) and expression profiling, genome-wide scoring of SNPs in different phases of Imatinib-treated CML will further help us to understand the resistance mechanism to TKIs.

At the transcript level, we were able to cluster TKI-sensitive and TKI-resistant cases and, after comparing, we identified the up-regulation of autophagy, complement, Tie-2 and Basigin signaling mediated homeostasis, protein ubiquitination, stem cell and down-regulation of immune system and TGF-beta pathways. Deregulation of these pathways was accompanied by low CNVs in CP-new and CP-UT-TKI-sensitive cases with undetectable BCR-ABL copies. High CNVs (previously reported gain of 9q34) were observed in BCR-ABL-independent and -dependent TKI, non-sensitive-CP-UT/AP-UT/B-UT and B-new samples. Further, using genotyping arrays, we assessed associations between individual SNPs and CML-resistance risk using odds ratios (ORs) and 95% confidence intervals (CIs) derived from logistic regression models. We identified that rsID239798 and 9475077 associated with the FAM83B gene, which may be directly related to treatment resistance in Imatinib-treated unrelated CML cases versus controls.

This analysis will be useful for a large segment of the medical research community for clinical screening of TKI-resistant and TKI-sensitive CML cases and develop a signature profile, which may help in monitoring therapy.

RESULTS {#s2}
=======

Differential gene expression levels among 35 CML-samples {#s2_1}
--------------------------------------------------------

To identify significant differential gene expression levels between 4 control and 35 CML samples (including both TKI-treated and newly diagnosed cases), a one-way between-subjects ANOVA algorithm was used. Differentially expressed coding and non-coding transcript clusters were identified using default filtering criteria (fold-change (linear) \< -2 or fold-change (linear) \> 2 and ANOVA p value ≤0.05). The array that was used measures 67,528 genes, including both coding (44,699) and non-coding (22,829) genes. Out of the total number of genes, only 2,073 genes were differentially expressed (1,425 coding and 648 non-coding). Compared to control among all CML samples, 69 genes were up-regulated (49 coding and 20 non-coding), and 2,004 genes were down-regulated (1,376 coding and 628 non-coding). Hierarchical clustering of the gene-level data revealed distinct clustering of 35 CML samples, including tri-phasic-TKI-treated, new cases and four normal controls (p=0.01, Figure [1a](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"} ). When comparing clusters with copies of BCR-ABL, samples with un-detected copies of BCR-ABL (CP-UT, AP-UT and some of CP-new cases) were classified under the first cluster as non-sensitive cases (p=0.01). The second cluster-sub-cluster-I included all control samples, and the second cluster-sub-cluster-II included CP new cases and cases in which copies of BCR-ABL were undetectable. The third cluster included samples showing ≥1-10% copies of BCR-ABL (CP-UT, AP-UT and new blast cases) (Table [1](#T1){ref-type="table"}).

![**(a)** Hierarchical clustering of the gene-level data revealed a distinct clustering of subgroups of all CML cases (35) and control (4) using default filtering criteria (fold-change (linear) \< -2 or fold-change (linear) \> 2 and ANOVA p value ≤0.05). **(b)** Gene level differential expression between 4 control and 35 CML samples using strict criteria (fold-change=2, p=0.001, and FDR p value=0.05) and considering only NM IDs, a highly significant down-regulation of 18 genes based upon which three clusters were formed.](oncotarget-09-30385-g001){#F1}

###### Hierarchical clustering of the gene-level data revealed distinct clustering of 35 samples of CML including all the three phases and 4 normal controls at p=0.01

  Cluster-I-Sub-cluster-I                                                                                                                                                                                    
  ------------------------------- ----------- ------ ------------ ----------- -------------------------------------------------------------------------------------------------- ------------ -------------- ---------------------------------------------------------------------------------------------------------------------
  CML-69                          AP-UT-69    40/F   16-04-2015   3 months    Imatinib                                                                                           04-11-2014   14.08          Imatinib non-sensitive
                                                                                                                                                                                 29-04-2015   9.75           
  CML-83                          CP-New-83   70/M   27-04-2015   New         Imatinib                                                                                           18-04-2015   77.02          Not known
  CML-86                          AP-UT-86    49/M   27-04-2015   5 months    Imatinib and march 2015 Nilotinib                                                                  25-11-2014   18.04          Imatinib non-sensitive
                                                                                                                                                                                 01-05-2015   2.45           
  CML-72                          AP-UT-72    45/M   16-04-2015   6 months    Imatinib and june 2015 Nilotinib                                                                   16-10-2014   25.19          Imatinib non-sensitive and Nilotinib sensitive (TKI-sensitive)
                                                                                                                                                                                 01-05-2015   5.45           
  CML-73                          CP-New-73   50/M   22-04-2015   New         Imatinib                                                                                           25-04-2015   73.8           Not known
  CML-70                          AP-UT-70    30/M   16-04-2015   1.0 year    Imatinib and december 2014 nilotinib                                                               10-01-2015   20             Imatinib and Nilotinib non-sensitive(TKI-non sensitive)
                                                                                                                                                                                 22-04-2015   1.63           
  CML-71                          CP-UT-71    52/M   16-04-2015   8.2 yrs     Initially Hydab, Unidrea and since october 2012 Imatinib and switched to nilotinib December 2014   15-04-2014   20             Initially Hydab, Unidrea and since october 2012 Imatinib and switched to nilotinib December 2014, TKI-non-sensitive
                                                                                                                                                                                 22-06-2015   8.63           
  **Cluster-I-Sub-cluster-II**                                                                                                                                                                               
  CML-55                          CP-UT-55    60/M   06-02-2015   3 months    Hydroxyurea, Zyloric and Imatinib                                                                  02-12-2014   98.47          Hydroxyurea, Zyloric and Imatinib non- sensitive
                                                                                                                                                                                 01-05-2015   9.75           
  CML-56                          CP-UT-56    43/F   09-02-2015   1.0 yr      Hydroxyurea, Zyloric and Imatinib                                                                  29-02-2014   89.5           Hydroxyurea, Zyloric and Imatinib non-sensitive
                                                                                                                                                                                 24-03-2015   1.2            
  CML-58                          CP-UT-58    32/F   09-02-2015   9 months    Hydroxyurea, Zyloric and Imatinib                                                                  12-04-2015   58.75          Hydroxyurea, Zyloric and Imatinib non-sensitive
                                                                                                                                                                                 12-04-2015   9.8            
  CML-62                          AP-UT-62    42/M   09-04-2015   4.4 yrs     Unidrea, Imatinib and since February 2014 Nilotinib                                                06-06-2014   14.96          Uridrea, Imatinib and Nilotinib non-sensitive (TKI-non-sensitive)
                                                                                                                                                                                 22-06-2015   4.03           
  CML-65                          CP-UT-65    43/M   20-04-2015   7.9 yrs     Hydroxyurea, Zyloric and Imatinib later Nilotinib                                                  24-06-2014   18.95          Hydroxyurea, Zyloric Imatinib and Nilotinib was sensitive (TKI-non-sensitive)
                                                                                                                                                                                 22-04-2015   4.63           
  CML-57                          CP-UT-57    42/F   09-02-2015   7 months    Hydroxyurea, Zyloric and Imatinib                                                                  22-07-2014   67.45          Hydroxyurea, Zyloric and Imatinib non-sensitive
                                                                                                                                                                                 22-04-2015   8              
  CML-59                          CP-UT-59    15/M   01-04-2015   3 months    Hydroxyurea, Zyloric and Imatinib                                                                  11-12-2014   15.75          Hydroxyurea, Zyloric and Imatinib non-sensitive
                                                                                                                                                                                 29-04-2015   9.75           
  CML-14                          B-New-14    35/F   29-05-2014   New         Hydroxyurea, Zyloric and Imatinib                                                                  09-06-2014   85.56          Not known
  All controls                                                                                                                                                                                               
  **Cluster-2-sub cluster-II**                                                                                                                                                                               
  CML-10                          CP-New-10   20/M   28-05-2014   New         Imatinib                                                                                           28-05-2014   120            Not known
                                                                                                                                                                                 06-02-2015   0.95           
  CML-07                          CP-UT-07    41/M   22-05-2014   7.2 yrs     Imatinib                                                                                           28-02-2007   100%           Imatinib sensitive
                                                                                                                                                                                 22-07-2014   not detected   
  CML-6                           CP-UT-6     24/M   22-05-2014   7 months    Imatinib                                                                                           21-11-2013   75             Imatinib sensitive
                                                                                                                                                                                 17-06-2014   not detected   
  CML-04                          CP-UT-4     14/M   22-05-2014   1.2 year    Imatinib                                                                                           15-03-2013   100            Imatinib sensitive
                                                                                                                                                                                 06-09-2014   not detected   
  CML-02                          CP-UT-2     50/M   22-05-2014   4 yrs       Initially with Droxygel (Antacid), Unidrea and later with Imatinib                                 14-02-2013   100%           Initially with Droxygel (Antacid), Unidrea and later with Imatinib-sensitive
                                                                                                                                                                                 20-03-2014   not detected   
  CML-1                           AP-UT-1     35/M   22-05-2014   1.8 yrs     Imatinib                                                                                           30-08-2012   26             Imatinib sensitive
  CML-20                          CP-UT-20    33/F   05-06-2014   1 month     Imatinib                                                                                           21-05-2014   97.54          NA
  **Cluster-3-sub cluster-I**                                                                                                                                                                                
  CML-34                          B-New-34    24/M   12-06-2014   New         Imatinib and since February 2015 Nilotinib                                                         20-06-2014   35.63          Imatinib non-sensitive
                                                                                                                                                                                 27-11-2014   95.37          
  CML-09                          CP-New-9    46/M   28-05-2014   New         Imatinib                                                                                           28-05-2014   100            Not known
  CML-32                          AP-UT-32    27/F   12-06-2014   15 yrs      Initially treated with Myeleron, Hydab, Zyloric since may 2005 on Imatinib                         13-07-2014   55.63          Initially treated with Myeleron, Hydab, Zyloric since may 2005 on Imatinib-non-sensitive
                                                                                                                                                                                 17-11-2014   35.37          
  **Cluster-3-sub cluster-II**                                                                                                                                                                               
  CML-13                          CP-UT-13    50/M   29-05-2014   7.1 yrs     Droxygel (Antacid), Unidrea and Imatinib                                                           20-02-2014   30             Droxygel (Antacid), Unidrea and Imatinib sensitive
                                                                                                                                                                                 12-03-2015   0.1            
  CML-21                          CP-UT-21    60/M   05-06-2014   3.8 yrs     Droxygel (Antacid), Unidrea and Imatinib                                                           14-11-2013   75             Droxygel (Antacid), Unidrea and Imatinib sensitive
                                                                                                                                                                                 31-07-2014   0.11           
  CML-19                          B-New-19    28/M   29-05-2014   New         Imatinib                                                                                           15-05-2014   100            Not known
  CML-11                          CP-UT-11    33/F   28-05-2014   4.2 yrs     Hydab and Imatinib                                                                                 21-04-2010   97.54          Hydab and Imatinib sensitive
                                                                                                                                                                                 21-05-2014                  Not detectable
  CML-36                          CP-UT-36    23/M   03-07-2014   6.10 yrs    Initially Hydab and presently on Imatinib                                                          20-02-2010   30             Initially Hydab and Imatinib sensitive
                                                                                                                                                                                 30-10-2014   0.11           
  **Cluster-3-sub cluster-III**                                                                                                                                                                              
  CML-93                          CP-UT-93    60/M   08-06-2015   11 months   Imatinib                                                                                           14-05-2014   100            Imatinib non-sensitive
                                                                                                                                                                                 11-03-2015   70.13          
  CML-68                          CP-UT-68    28/M   16-04-2015   4 months    Imatinib                                                                                           22-09-2014   45.2           Imatinib non-sensitive
                                                                                                                                                                                 22-04-2015   16.1           
  CML-91                          CP-UT-91    66/F   08-06-2015   6 months    Imatinib                                                                                           10-09-2014   38.52          Imatinib non-sensitive
                                                                                                                                                                                 22-04-2015   26.1           
  CML-63                          CP-UT-63    37/M   09-04-2015   7 months    Imatinib                                                                                           21-08-2014   100            Imatinib non-sensitive
                                                                                                                                                                                 09-04-2015   80             
  CML-87                          CP-UT-87    45/F   08-06-2015   2.9 yrs     Imatinib                                                                                           01-07-2015   86             Imatinib non-sensitive

Both sub-cluster-I and II of I-cluster included non-sensitive cases with un-detected copies of BCR-ABL samples (Chronic Phase under treatment; CP-UT, accelerated phase under treatment; AP-UT and some of Chronic Phase-new; CP-new cases) In cluster-I sub-cluster-II all were treated with Hydroxyurea, Zyloric and Imatinib and were non-sensitive to the treatment. The second cluster-sub-cluster-I included all control samples and second cluster-sub-cluster-II included CP-new cases and cases where copies of BCR-ABL were undetectable. Third cluster included samples showing \> or = 1 to 10% copies of BCR-ABL samples (CP-UT, AP-UT and new blast cases). In cluster-3 sub-cluster-I one patient was initially treated with Myeleron (Busulfan-15 years back), Hydab, Zyloric and later with Imatinib and in cluster-3 sub-cluster-II the samples except CML-19 all other were treated with Droxygel (Antacid), Unidrea/Hydab and Imatinib.

In the first cluster-sub-cluster-II, the CML-55, 56, 57, 58, 59 samples were all from patients treated with Hydroxyurea, Zyloric and Imatinib and were non-sensitive to treatment but for shorter time period (all within one year). In the third cluster sub-cluster-I, one patient was initially treated with Myeleron (Busulfan 15 years earlier), Hydab, and Zyloric and then later with Imatinib and then developed resistance. The third cluster sub-cluster-II contained samples treated with Droxygel (Antacid), Unidrea/Hydab and Imatinib for a longer time period (3.8 years-7.1 years).

[Supplementary Table 1](#SD2){ref-type="supplementary-material"} shows the differential expression of genes between 4 control and 35 CML samples, including both TKI-treated and fresh diagnosed cases (p=0.01, fold-change=2, default FDR p value). These differentially expressed genes showed highly significant involvement with the Retinoblastoma (RB) (24 up-regulated and 1 down-regulated), cell cycle (14 up-regulated and 2 down-regulated), DNA replication (8 up-regulated), DNA IR-damage and cellular response via ATR (9 up-regulated and 1 down-regulated), allograft rejection (10 down-regulated), T cell antigen receptor (TCR) signaling pathway (9 down-regulated), Vitamin D receptor pathway (12 down-regulated), histone modifications (7 up-regulated), gastric cancer networks 1 and 2 (5 and 6 genes up-regulated, respectively), G1 to S cell cycle control (6 up-regulated and 1 down-regulated), mitotic G1-G1/S phases (12 up-regulated), spinal cord injury (2 up-regulated and 6 down-regulated), hair follicle development: cyto-differentiation (1 up-regulated and 6 down-regulated) and TGF-beta signaling pathways (2 up-regulated and 6 down-regulated, [Supplementary Table 2a](#SD3){ref-type="supplementary-material"}).

With strict criteria (fold-change=2, p=0.001, and FDR p value=0.05) and considering only NM IDs on gene level differential expression between 4 control and 35 CML samples, a highly significant down-regulation of 18 genes was identified upon which the following three clusters were formed: the first cluster included control samples CML-20 and CML-63; the second cluster included CML-4, 7, 91, 93, 1, 11, 19, 6 and 10; and the third cluster included three sub-clusters-I (21, 36, 72, 73, 71, 83, 65, and 70), sub-cluster-II (32, 55, 9, 58, 14, 34, and 69) and sub-cluster-III (56, 59, 86, 62, 57, 2, 13, 68, and 87, Figure [1b](#F1){ref-type="fig"}).

At a significance level of p=0.001 and an FDR p value=0.05, 18 genes showed significant down-regulation (p=0.05) among 36 pathways in CML, including the highly significant PDGFR-beta pathway (significance of 3.77 at p=0.000171), the TGF-beta receptor signaling pathway (significance of 3.21 at p=0.000618), the spinal cord injury pathway (significance of 2.56 at p=0.002758), the TGF-beta signaling pathway (significance of 2.44 at p=0.003649), and the MAPK signaling pathway (significance of 1.94 at p=0.011546, [Supplementary Table 2b](#SD3){ref-type="supplementary-material"}).

Exon-specific expression among control and 35-CML samples {#s2_2}
---------------------------------------------------------

Relative exon-specific expression was measured between two conditions (control and all 35-CML samples) after excluding gene level data and passing through default filtering criteria (Splicing Index (linear) \< -2 or Splicing Index (linear) \> 2, ANOVA p value \< 0.05, a gene must be expressed in both conditions, a PSR/Junction must be expressed in at least one condition, and a gene must contain at least one PSR) using the following algorithms: 1.) Splicing Index; 2.) one-way between-subjects ANOVA (unpaired); 3.) false discovery rate \< 0.05; 4.) use an eligible PSR to determine gene expression if it presents in \>=50% of all transcript isoforms; 5.) a gene is expressed in a sample if \>=50% of its eligible PSRs have DABG p value \< 0.05; 6.) a condition has this gene expressed if \>=50% of its samples express this gene; and 7.) a PSR/Junction is expressed in a condition if \>=50% of samples have DABG p value \< 0.05 among the samples analyzed.

However, on applying strict criteria (Exon-Splicing Index (linear) \< -10 or Splicing Index (linear) \> 10, exon ANOVA p value \< 0.001, exon FDR p value \< 0.05, fold-change \< -10 or \> 10 for genes expressed in both conditions), we observed 7.59-, 15.22- and 5.09-fold down-regulation of IL-2-inducible T cell kinase (ITK-exon SI -10.28, exon p value=0.0000123, exon FDR p value=0.0201), FBJ murine osteosarcoma viral oncogene homolog (FOS-exon SI -12.57, exon p value=0.000000587, exon FDR p value=0.006), and src kinase associated phosphoprotein 1 (SKAP1-exon SI -10.37, exon p value= 0.0000354, exon FDR p value=0.031), respectively, among CML samples. However, Myeloperoxidase (MPO-exon SI -30.08, exon p value=0.0001, exon FDR p value=0.044), Thymidylate synthetase (TYMS-exon SI= -15.08, exon p value=0.0000896, exon FDR p value=0.044) and TPX2, microtubule-associated (TPX2-exon SI=13.79, exon p value= 0.0001, exon FDR p value=0.046) showed up-regulation of 121.81-, 10.12- and 7.56-fold, respectively, among CML cases. After submitting these genes to the Reactome Pathway database, we identified ITK, FOS and SKAP1 mediated down-regulation of the immune system ([Supplementary Table 3](#SD4){ref-type="supplementary-material"}). MPO, TPX2, TYMS specifically up-regulated cell cycle pathways and individually, TPX2 mediated the up-regulation of phosphorylation altering the transcriptional regulation of TP53 activity and TYMS-related G1/S-Specific transcription through interconversion of nucleotide di- and triphosphates. Further, MPO enhanced neutrophil degranulation, thereby affecting the innate immune system ([Supplementary Table 3](#SD4){ref-type="supplementary-material"}).

Copy number variation profiling of 34 CML-samples {#s2_3}
-------------------------------------------------

CNV profiling was completed for 39 CML-samples (34 CML and five control samples), and the results were analyzed using Nexus version 7.5 (Biodiscovery, Inc. CA USA). Samples were further categorized on the basis of CNVs, percent loss of heterozygosity (LOH) and percent genome change (Table [2a](#T2a){ref-type="table"}). In group I, CP-new and B-New cases (CML9, 10, 14) and CP-UT cases with un-detected BCR-ABL levels (CML56, 57, 58, CML55, 59) showed low copy number variation, i.e., there were no significant gains, but there were losses of HOXA9, HOXA11, HOXA13 (7p15.2) and CDK4 (12q14.1, Table [2b](#T2b){ref-type="table"} and [2c](#T2c){ref-type="table"}). In group II, high CNVs were observed in both samples with undetectable and \<20% BCR-ABL copies, including both sensitive and non-sensitive cases and \>20% BCR-ABL copies (AP-UT-22, 37, 38 and B-New-34, B-UT-47, 48)\] (Table [2b](#T2b){ref-type="table"}). On aggregate analysis, the high CNVs-TKIs non-sensitive group showed significant gains of SDHB (1p36.13), FGFR3, WHSC1 (4p16.3), FNBP1, ABL1, NUP214, TSC1, RALGDS (9q34.11 - q34.2), YWHAE (17p13.3), CDK12 (17q12) and U2AF1 (21q22.3), with some important losses as listed in Table [2c](#T2c){ref-type="table"}.

###### Percent genome change identified in chronic myeloid leukemia samples of different phases undergoing treatment (Chronic Phase under treatment; CP-UT, accelerated phase under treatment; AP-UT and Blast Phase under treatment; B-UT ) and new cases (Chronic Phase-new; CP-new and Blast new; B-new) cases through copy number and somatic mutation related molecular inversion probe based array

       Sample   Quality    Total CN aberrations   \% LOH     \% Genome Changed   OS-MAPD    OS-ndSNPQC   OS-CelPair Check Status   OS-nd WavinessSd   OS-% Aberr. Cells   OS-Ploidy   OS-Low Diploid Flag
  ---- -------- ---------- ---------------------- ---------- ------------------- ---------- ------------ ------------------------- ------------------ ------------------- ----------- ---------------------
  1    CML-09   1.57E-01   62                     7.55E-01   4.23E-01            2.69E-01   3.30E+01     Pass                      1.90E-01           homogeneous         2.00E+00    No
  2    CML-10   4.92E-01   60                     3.42E+01   3.53E+00            4.68E-01   1.01E+01     Pass                      2.16E-01           NA                  NaN         Yes
  3    CML-14   1.60E-01   34                     2.61E+00   2.88E-01            2.69E-01   3.17E+01     Pass                      1.38E-01           homogeneous         2.00E+00    No
  4    CML-55   3.64E-01   79                     8.32E+00   1.20E+01            3.91E-01   1.31E+01     Pass                      8.74E-02           NA                  NaN         No
  5    CML-56   1.97E-01   91                     3.30E+00   2.66E+00            3.03E-01   1.23E+01     Pass                      1.59E-01           NA                  NaN         No
  6    CML-57   1.51E-01   80                     2.73E+00   1.41E+00            2.68E-01   1.12E+01     Pass                      1.36E-01           NA                  NaN         No
  7    CML-58   1.53E-01   118                    5.50E+00   4.89E+00            2.69E-01   1.03E+01     Pass                      1.37E-01           NA                  NaN         No
  8    CML-59   4.12E-01   97                     1.13E+01   1.01E+01            4.35E-01   9.17E+00     Pass                      1.87E-01           NA                  NaN         No
  9    CML-13   1.77E-01   99                     2.01E+00   7.69E-01            2.84E-01   3.00E+01     Pass                      2.34E-01           homogeneous         2.00E+00    No
  10   CML-21   1.29E-01   81                     7.30E-01   4.99E-01            2.42E-01   4.16E+01     Pass                      1.53E-01           homogeneous         2.00E+00    No
  11   CML-23   1.60E-01   191                    3.56E+00   3.07E+00            2.58E-01   3.37E+01     Pass                      2.47E-01           70                  2.00E+00    No
  12   CML-26   1.35E-01   52                     1.34E+00   4.32E-01            2.50E-01   4.11E+01     Pass                      1.40E-01           homogeneous         2.00E+00    No
  13   CML-29   4.25E-01   63                     1.29E+01   1.45E+01            4.44E-01   1.05E+01     Pass                      1.09E-01           NA                  NaN         No
  14   CML-30   1.85E-01   226                    2.77E+00   4.18E+00            2.78E-01   3.27E+01     Pass                      2.68E-01           NA                  NaN         No
  15   CML-33   1.86E-01   172                    5.18E+00   3.03E+00            2.83E-01   2.72E+01     Pass                      2.18E-01           35                  2.00E+00    No
  16   CML-35   1.84E-01   106                    4.45E+00   9.00E-01            2.80E-01   3.03E+01     Pass                      2.54E-01           homogeneous         2.00E+00    No
  17   CML-36   2.03E-01   255                    7.45E+00   2.51E+00            2.93E-01   3.14E+01     Pass                      3.14E-01           95                  2.00E+00    No
  18   CML-43   1.53E-01   106                    1.56E+00   8.02E-01            2.61E-01   3.88E+01     Pass                      1.83E-01           homogeneous         2.00E+00    No
  19   CML-02   1.54E-01   84                     1.86E+00   5.93E-01            2.61E-01   3.47E+01     Pass                      2.23E-01           homogeneous         2.00E+00    No
  20   CML-04   1.72E-01   183                    3.43E+00   4.52E+00            2.74E-01   3.35E+01     Pass                      2.47E-01           NA                  NaN         No
  21   CML-07   1.64E-01   82                     1.98E+00   6.86E-01            2.77E-01   3.48E+01     Pass                      2.06E-01           homogeneous         2.00E+00    No
  22   CML-11   1.85E-01   158                    5.40E+00   1.38E+00            2.83E-01   3.14E+01     Pass                      2.92E-01           homogeneous         2.00E+00    No
  23   CML-48   1.70E-01   186                    3.22E+00   1.98E+00            2.71E-01   3.26E+01     Pass                      2.36E-01           50                  2.00E+00    No
  24   CML-49   2.17E-01   205                    6.64E+00   4.14E+00            3.12E-01   2.99E+01     Pass                      2.89E-01           85                  2.00E+00    No
  25   CML-51   2.39E-01   166                    4.62E+00   1.44E+00            3.29E-01   3.23E+01     Pass                      2.80E-01           homogeneous         2.00E+00    No
  26   CML-24   1.75E-01   295                    4.62E+00   3.65E+00            2.69E-01   3.41E+01     Pass                      2.84E-01           40                  2.00E+00    No
  27   CML-01   2.44E-01   197                    9.40E+00   5.90E+00            3.18E-01   1.67E+01     Pass                      2.74E-01           NA                  NaN         No
  28   CML-22   2.40E-01   86                     3.80E+00   1.00E+01            3.31E-01   1.82E+01     Pass                      1.49E-01           NA                  NaN         No
  29   CML-32   2.06E-01   241                    7.83E+00   3.12E+00            2.89E-01   2.92E+01     Pass                      2.98E-01           65                  2.00E+00    No
  30   CML-34   4.45E-01   231                    1.09E+01   1.26E+01            4.60E-01   2.06E+01     Pass                      2.83E-01           NA                  NaN         No
  31   CML-37   1.95E-01   135                    6.61E+00   1.20E+00            2.83E-01   2.51E+01     Pass                      2.73E-01           homogeneous         2.00E+00    No
  32   CML-38   2.08E-01   353                    5.44E+00   8.73E+00            3.01E-01   3.20E+01     Pass                      3.11E-01           NA                  NaN         No
  33   CML-47   2.82E-01   153                    3.53E+00   1.72E+00            3.56E-01   3.07E+01     Pass                      2.86E-01           homogeneous         2.00E+00    No
  34   CML- 8   1.94E-01   187                    1.04E+01   5.75E+00            2.81E-01   3.04E+01     Pass                      3.46E-01           85                  2.00E+00    No

###### Nexus 7.5 analysed chronic myeloid leukemia samples of different undergoing treatment (Chronic Phase under treatment; CP-UT, accelerated phase under treatment; AP-UT and Blast Phase under treatment; B-UT ) and new cases (Chronic Phase-new; CP-new and Blast new; B-new) cases: clustered on the basis of copy number variations in relation to BCR-ABL transcript levels

  Sample-ID                                                                            CML-Phases and treatment status   Age/Sex   Sample collection date   Time of Assessment   Treatment                                                                           Date         BCR-ABL%         Comments based on BCR-ABL
  ------------------------------------------------------------------------------------ --------------------------------- --------- ------------------------ -------------------- ----------------------------------------------------------------------------------- ------------ ---------------- -------------------------------------------------------------------------------------------------
  **Low CNVs group with undetectable BCR-ABL transcript levels, new cases or \<10%**                                                                                                                                                                                                               
  CML-09                                                                               CP-New-9                          46/M      28-05-2014               New                  Imatinib                                                                            28-05-2014   100              \-
  CML-14                                                                               B-New-14                          35/F      29-05-2014               New                  Hydroxyurea, Zyloric and Imatinib                                                   09-06-2014   85.56            \-
  CML-10                                                                               CP-New-10                         20/M      28-05-2014               New                  Imatinib                                                                            28-05-2014   120              \-
                                                                                                                                                                                                                                                                                  0.95             
  CML-55                                                                               CP-UT-55                          60/M      06-02-2015               3 months             Hydroxyurea, Zyloric and Imatinib                                                   02-12-2014   98.47            Hydroxyurea, Zyloric and Imatinib non-sensitive
                                                                                                                                                                                                                                                                     01-05-2015   9.75             
  CML-56                                                                               CP-UT-56                          43/F      09-02-2015               1.0 yr               Hydroxyurea, Zyloric and Imatinib                                                   29-02-2014   89.5             Hydroxyurea, Zyloric and Imatinib non sensitive
                                                                                                                                                                                                                                                                     24-03-2015   1.2              
  CML-57                                                                               CP-UT-57                          42/F      09-02-2015               7 months             Hydroxyurea, Zyloric and Imatinib                                                   22-07-2014   67.45            Hydroxyurea, Zyloric and Imatinib non sensitive
                                                                                                                                                                                                                                                                     22-04-2015   8                
  CML-58                                                                               CP-UT-58                          32/F      09-02-2015               9 months             Hydroxyurea, Zyloric and Imatinib                                                   12-06-2014   58.75            Hydroxyurea, Zyloric and Imatinib sensitive
                                                                                                                                                                                                                                                                     12-04-2015   9.8              
  CML-59                                                                               CP-UT-59                          15/M      01-04-2015               3 months             Hydroxyurea, Zyloric and Imatinib                                                   11-12-2014   15.75            Hydroxyurea, Zyloric and Imatinib sensitive
                                                                                                                                                                                                                                                                     29-04-2015   9.75             
  **High CNVs in undetectable/\<20% BCR-ABL transcript**                                                                                                                                                                                                                                           
  CML-13                                                                               CP-UT-13                          50/M      29-05-2014               7.1 yrs              Droxygel (Antacid), Unidrea and Imatinib                                            20-02-2014   30               Droxygel (Antacid), Unidrea and Imatinib sensitive
                                                                                                                                                                                                                                                                     12-03-2015   0.1              
  CML-21                                                                               CP-UT-21                          60/M      05-06-2014               3.8 yrs              Droxygel (Antacid), Unidrea and Imatinib                                            14-11-2013   75               Droxygel (Antacid), Unidrea and Imatinib sensitive
                                                                                                                                                                                                                                                                     31-07-2014   0.11             
  CML-23                                                                               CP-UT-23                          40/M      05-06-2014               2.4 yrs              Unidrea and Imatinib, Nilotinib                                                     31-07-2013   28.35            Unidrea Imatinib and Nilotinib-non-sensitive
                                                                                                                                                                                                                                                                     13-05-2014   11.9             
  CML-26                                                                               CP-UT-26                          32/M      05-06-2014               2.1 yrs              Imatinib                                                                            26-03-2012   150              Imatinib non-sensitive
                                                                                                                                                                                                                                                                     10-05-2014   13.6             
  CML-29                                                                               B-UT-29                           35F       05-06-2014               1 month              Imatinib                                                                            04-05-2014   89.12            Imatinib non-sensitive
                                                                                                                                                                                                                                                                     01-08-2014   15.89            
  CML-30                                                                               CP-New-30                         22/M      12-06-2014               \-                   Imatinib                                                                            24-06-2014   11               Not known
                                                                                                                                                                                                                                                                     30-09-2014   12.65            
  CML-33                                                                               AP-UT-33                          20/M      28-06-2014               2 yrs                Imatinib                                                                            24-07-2012   100              Imatinib non-sensitive
                                                                                                                                                                                                                                                                     27-06-2014   12.18            
  CML-35                                                                               AP-UT-35                          28/F      03-07-2014               6.3 yrs              Imatinib                                                                            24-07-2010   100              Imatinib non-sensitive
                                                                                                                                                                                                                                                                     13-04-2013   0.02             
                                                                                                                                                                                                                                                                     03-07-2014   8.56             
  CML-36                                                                               CP-UT-36                          23/M      03-07-2014               6.10 yrs             Hydab and Imatinib                                                                  20-02-2010   30               Hydab and Imatinib sensitive
                                                                                                                                                                                                                                                                     30-10-2014   0.16             
  CML-43                                                                               CP-UT-43                          27/M      10-07-2014               7 yrs                Initially Hydroxyurea and Imatinib                                                  23-02-2012   55.89            Hydroxyurea and Imatinib-sensitive
                                                                                                                                                                                                                                                                     17-06-2014   11.18            
                                                                                                                                                                                                                                                                     14-03-2015   0                
  CML-24                                                                               CP-UT-24                          26/F      05-06-2014               8.5 yrs              Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib   24-04-2014   30               Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib-non-sensitive
                                                                                                                                                                                                                                                                     21-05-2015   15.85            
  CML-02                                                                               CP-UT-2                           50/M      22-05-2014               4 yrs                Droxygel (Antacid), Unidrea and Imatinib                                            14-02-2013   100%             Droxygel (Antacid), Unidrea and Imatinib-sensitive
                                                                                                                                                                                                                                                                     20-03-2014   not detected     
  CML-04                                                                               CP-UT-4                           14/M      22-05-2014               1.2 yrs              Imatinib                                                                            15-07-2013   100              Imatinib sensitive
                                                                                                                                                                                                                                                                     06-09-2014   not detected     
  CML-07                                                                               CP-UT-7                           41/M      22-05-2014               7.2 yrs              Imatinib                                                                            28-02-2007   100%             Imatinib-sensitive
                                                                                                                                                                                                                                                                     22-07-2014   not detected     
  CML-11                                                                               CP-UT-11                          33/F      28-05-2014               4.2 yrs              Hydab and Imatinib                                                                  21-04-2010   97.54            Hydab and Imatinib sensitive
                                                                                                                                                                                                                                                                     21-05-2014   Not detectable   
  CML-48                                                                               CP-UT48                           33/M      31-07-2014               10.4 yrs             Initially Hydroxyurea and since December 2004 Imatinib                              01-10-2004   100              Initially Hydroxyurea and since December 2004 Imatinib non-sensitive
                                                                                                                                                                                                                                                                     29-05-2014   9.94             
  CML-49                                                                               Blast-UT-49                       15/M      31-07-2014               1.4 yrs              Imatinib                                                                            06-03-2013   100              Imatinib non-sensitive
                                                                                                                                                                                                                                                                     30-06-2014   not detected     
  CML-51                                                                               CP-UT-51                          60/M      31-07-2014               25 yrs               Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib   12-05-2013   30               Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib non-sensitive
                                                                                                                                                                                                                                                                     11-06-2014   8.98             
  CML-01                                                                               AP-UT-1                           35/M      22-05-2014               1.8 yrs              Imatinib                                                                            30-08-2012   26               Imatinib sensitive
  **High CNVs with BCR-ABL transcript levels \>20%**                                                                                                                                                                                                                                               
  CML-22                                                                               AP-UT-22                          40/M      05-06-2014               5.2 yrs              Hydab and Imatinib                                                                  17-11-2013   39.07            Hydab and Imatinib non-sensitive
                                                                                                                                                                                                                                                                     05-08-2014   20.11            
  CML-32                                                                               AP-UT-32                          27/F      12-06-2014               15 yrs               Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib   13-07-2014   55.63            Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib-non-sensitive
                                                                                                                                                                                                                                                                     17-11-2014   35.37            
  CML-34                                                                               B-New-34                          24/M      12-06-2014               New                  Imatinib and since February 2015 Nilotinib                                          20-06-2014   35.63            Imatinib and Nilotinib non-sensitive
                                                                                                                                                                                                                                                                     27-11-2014   95.37            
  CML-37                                                                               AP-UT-37                          27/F      03-07-2014               8 months             Imatinib                                                                            01-04-2013   100              Imatinib non-sensitive
                                                                                                                                                                                                                                                                     03-07-2014   50               
  CML-38                                                                               AP-UT-38                          60/M      03-07-2014               1.5 yrs              Imatinib                                                                            29-03-2013   79.01            Imatinib non-sensitive
                                                                                                                                                                                                                                                                     24-06-2014   35.12            
  CML-47                                                                               B-UT-47                           48/M      17-07-2014               3 months             Imatinib and 29-05-2014 Uridrea                                                     27-07-2014   40.12            Unidrea and Imatinib non-sensitive
                                                                                                                                                                                                                                                                     29-10-2014   32.45            
  CML-08                                                                               B-UT-8                            24/M      22-05-2014               8 months             Imatinib                                                                            26-09-2013   100              Imatinib non-sensitive
                                                                                                                                                                                                                                                                     20-06-2014   26.89            

###### Aggregate analysis through Nexus 7.5 of low and high copy number variation group in relation to BCR-ABL levels

  Low CNVs with undetectable BCR-ABL (TKIs-sensitive) group                                                  
  -------------------------------------------------------------------------------------- --------- --------- -----------------------------------
  Cytoband Location                                                                      Event     P-Value   CancerGeneCensus-Sanger.txt
  7p15.2                                                                                 CN Loss   0.001     HOXA9, HOXA11, HOXA13
  12q14.1                                                                                CN Loss   0.002     CDK4
  **High CNVs (CN loss)-BCR-ABL dependent and independent (TKIs-non-sensitive) group**                       
  Cytoband Location                                                                      Event     P-Value   CancerGeneCensus-Sanger.txt
  1p36.33 - p36.32                                                                       CN Loss   0.007     TNFRSF14
  1p36.32                                                                                CN Loss   0.007     PRDM16
  1p32.1                                                                                 CN Loss   0.007     JUN
  2p24.3                                                                                 CN Loss   0.002     MYCN
  2p23.1                                                                                 CN Loss   0.002     ALK
  2p16.1                                                                                 CN Loss   0.002     REL
  2q13                                                                                   CN Loss   0.001     PAX8
  2q31.1                                                                                 CN Loss   0.001     HOXD13, HOXD11
  5q13.1                                                                                 CN Loss   0.002     PIK3R1
  5q32                                                                                   CN Loss   0.002     PDGFRB
  5q35.1                                                                                 CN Loss   0.002     NPM1
  5q35.2                                                                                 CN Loss   0.002     NSD1
  6p21.33                                                                                CN Loss   0.006     POU5F1
  7q31.2                                                                                 CN Loss   0.002     MET
  10q11.21                                                                               CN Loss   0.001     RET
  10q23.31                                                                               CN Loss   0.001     PTEN
  11p15.5                                                                                CN Loss   0.01      HRAS
  11q13.3                                                                                CN Loss   0.004     CCND1
  13q12.2                                                                                CN Loss   0.019     CDX2
  13q14.2                                                                                CN Loss   0.019     RB1
  15q24.1                                                                                CN Loss   0.001     PML
  15q26.1                                                                                CN Loss   0.012     IDH2
  16p13.3                                                                                CN Loss   0.002     TSC2
  19p13.3                                                                                CN Loss   0.017     STK11
  19p13.3                                                                                CN Loss   0.017     STK11, TCF3
  19q13.2                                                                                CN Loss   0.012     AKT2
  19q13.2                                                                                CN Loss   0.012     CD79A
  20q13.32                                                                               CN Loss   0.019     GNAS
  21q22.11                                                                               CN Loss   0.001     OLIG2
  **High CNVs (CN gain)-BCR-ABL dependent and independent (TKIs-non-sensitive) group**                       
  Cytoband Location                                                                      Event     P-Value   CancerGeneCensus-Sanger.txt
  1p36.13                                                                                CN Gain   0.002     SDHB
  Cytoband Location                                                                      Event     P-Value   CancerGeneCensus-Sanger.txt
  4p16.3                                                                                 CN Gain   0.008     FGFR3, WHSC1
  9q34.11 - q34.2                                                                        CN Gain   0.004     FNBP1, ABL1, NUP214, TSC1, RALGDS
  17p13.3                                                                                CN Gain   0.001     YWHAE
  17q12                                                                                  CN Gain   0.004     CDK12
  21q22.3                                                                                CN Gain   0.022     U2AF1

Analysis of 13 CML samples with common transcriptomics and CNV {#s2_4}
--------------------------------------------------------------

The 13 CML samples with common transcriptomics and CNV profiles were separately compared to control through TAC using the same filter criteria (p value = 0.001 and FDR value p value = 0.001). CNV-based clustering was similar to transcript-based clustering, except for samples CML 2, 4 and 10. These samples were in the same transcript cluster as undetectable-BCR-ABL transcript (Cluster-II-sub-cluster-II); in the CNV-based cluster, samples 2 and 4 were grouped in the higher CNV group (undetectable/\<20% BCR-ABL transcript), and CML-10 was grouped in the CNV group with undetectable BCR-ABL transcript levels, new cases or un-detected BCR-ABL (Table [3](#T3){ref-type="table"}).

###### Transcriptionally clustered (at the significance level p=0.001 and FDR p=0.0001 and Fold Change\<-4 or \>4) 13-CML samples (Chronic Phase-new; CP-new and Blast new; B-new and Chronic Phase under treatment; CP-UT) which were also processed for CNVs-profiling

  Cluster-I                                                                                                                                                       
  ----------------- ----------- ------ ------------ ---------- -------------------------------------------------------------------- ------------ ---------------- -----------------------------------------------------------------------------------------------
  CML-10            CP-New-10   20/M   28-05-2014   New        Imatinib                                                             28-05-2014   120              Not known
                                                                                                                                    06-02-2015   0.95             
  CML-02            CP-UT-2     50/M   22-05-2014   4 yrs      Initially with Droxygel (Antacid), Unidrea and later with Imatinib   14-02-2013   100%             Initially with Droxygel (Antacid), Unidrea and later with Imatinib-sensitive (TKI- sensitive)
                                                                                                                                    20-03-2014   0.12             
  CML-04            CP-UT-4     14/M   22-05-2014   1.2 year   Imatinib                                                             15-03-2013   100              Imatinib sensitive (TKI- sensitive)
                                                                                                                                    06-09-2014   0.95             
  **Cluster-II**                                                                                                                                                  
  CML-13            CP-UT-13    50/M   29-05-2014   7.1 yrs    Droxygel (Antacid), Unidrea and Imatinib                             20-02-2014   30               Droxygel (Antacid), Unidrea and Imatinib sensitive (TKI- sensitive)
                                                                                                                                    12-03-2015   0.1              
  CML-21            CP-UT-21    60/M   05-06-2014   3.8 yrs    Droxygel (Antacid), Unidrea and Imatinib                             14-11-2013   75               Droxygel (Antacid), Unidrea and Imatinib sensitive (TKI-sensitive)
                                                                                                                                    31-07-2014   0.11             
  CML-36            CP-UT-36    23/M   03-07-2014   6.10 yrs   Initially Hydab and presently on Imatinib                            20-02-2010   30               Initially Hydab and Imatinib sensitive (TKI- sensitive)
                                                                                                                                    30-10-2014   0.11             
  CML-11            CP-UT-11    33/F   28-05-2014   4.2 yrs    Hydab and Imatinib                                                   21-04-2010   97.54            Hydab and Imatinib (TKI-sensitive)
                                                                                                                                    21-05-2014   Not detectable   
  **Cluster-III**                                                                                                                                                 
  CML-55            CP-UT-55    60/M   06-02-2015   3 months   Hydroxyurea, Zyloric and Imatinib                                    02-12-2014   98.47            Hydroxyurea, Zyloric and Imatinib non- sensitive
                                                                                                                                    01-05-2015   9.75             
  CML-56            CP-UT-56    43/F   09-02-2015   1.0 yr     Hydroxyurea, Zyloric and Imatinib                                    29-02-2014   89.5             Hydroxyurea, Zyloric and Imatinib sensitive
                                                                                                                                    24-03-2015   1.2              
  CML-58            CP-UT-58    32/F   09-02-2015   9 months   Hydroxyurea, Zyloric and Imatinib                                    12-04-2015   58.75            Hydroxyurea, Zyloric and Imatinib sensitive
                                                                                                                                    12-04-2015   9.8              
  CML-57            CP-UT-57    42/F   09-02-2015   7 months   Hydroxyurea, Zyloric and Imatinib                                    22-07-2014   67.45            Hydroxyurea, Zyloric and Imatinib non-sensitive
                                                                                                                                    22-04-2015   8                
  CML-59            CP-UT-59    15/M   01-04-2015   3 months   Hydroxyurea, Zyloric and Imatinib                                    11-12-2014   15.75            Hydroxyurea, Zyloric and Imatinib non-sensitive
                                                                                                                                    29-04-2015   9.75             
  CML-14            B-New-14    35/F   29-05-2014   New        Hydroxyurea, Zyloric and Imatinib                                    09-06-2014   85.56            Not known

We identified up-regulation of 2,230 genes and down-regulation of 2,683 genes among Imatinib-resistant versus Imatinib-sensitive samples at the gene expression level after applying strict criteria \[ANOVA p value \< 0.001, FDR p value \<0.0001, and gene fold-change \< -4 or gene fold-change (linear) \> 4, Figure [2](#F2){ref-type="fig"}, Table [3](#T3){ref-type="table"}\]. We identified highly significant up-regulation of helicase-like transcription factor (HLTF, p= 0.00000000589, FDR p= 0.0000492), small nuclear ribonucleoprotein D1 polypeptide (SNRPD1, p= 0.000000012, FDR p= 0.0000492), 1-acylglycerol-3-phosphate O-acyltransferase 5 (AGPAT5, p= 0.0000000191, FDR p= 0.0000633), NOP58 ribonucleoprotein (NOP58, p= 0.0000000347, FDR p= 0.0000711), ribosome production factor 2 homolog (RPF2, p= 0.0000000502, FDR p= 0.0000865) and zinc finger protein 711 (ZNF711, p= 0.000000058, FDR p= 0.0000933). The genes were up-regulated in the AGPAT5-mediated triacylglyceride (significance=2.27, p=0.005357), glycerophospholipid synthesis (significance=1.51, p=0.0031133), NOP58-mediated SUMOylation of RNA binding proteins (significance=1.89, p=0.012906), SNRPD1-mediated metabolism of non-coding RNA (significance=1.84, p=0.014454), mRNA processing (significance=1.55, p=0.028078), HLTF-mediated Retinoblastoma (RB) in cancer (significance=1.7, p= 0.019966), and E3 ubiquitin ligases ubiquitinate target proteins pathways (significance=1.63, p=0.023481).

Further, when comparing Cluster III (TKI-resistant cases: CML-CP (CML-CP-UT 55-59, CML-B-14)) and Cluster I+Cluster-II (TKI sensitive cases: CML-CP-UT-2, 4, 10, 13, 21 and 36 and CML-CP-UT-11 as Imatinib/Imatinib plus other drugs-sensitive){ at the exon level using specific splicing index filter criteria \[(1.) Exon Splicing Index (linear) \< -4 or Exon Splicing Index (linear and exon expressed in at least one condition) \>4; 2.) ANOVA exon p value \< 0.001, exon FDR p value \<0.001; 3.) gene fold-change (linear and expressed in both conditions) \<-5 or Gene fold-change (linear) \> 5\], approximately 0.01% coding-genes passed filter criteria (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Considering SI at the exon level, lysosomal protein transmembrane 4 beta (LAPTM4B, FC17.99), piezo-type mechanosensitive ion channel component 2 (PIEZO2, FC-8.36), angiopoietin 1 (ANGPT1, FC-6.04), complement factor H (CFH, FC-6.39), helicase-like transcription factor (HLTF, FC-8.44), serine palmitoyltransferase, long-chain base subunit 3 (SPTLC3, FC-5.23), 1-acylglycerol-3-phosphate O-acyltransferase 5 (AGPAT5, FC-7.30), CD109 molecule (CD109 FC-6.07), and zinc finger protein 711 (ZNF711, FC-6.91) were up-regulated in TKI-resistant cases. The up-regulation resulted from the following: a cassette exon splicing event in LAPTM4B (0.46), PIEZO2 (0.32), ANGPT1 (0.29), CFH (0.28), HLTF (0.28), and SPTLC3 (0.26); splicing of an alternative 3\' acceptor site in AGPAT5 (0.22); and junctional splicing in CD109 and ZNF711. These genes were further processed using Reactome Pathway analysis software (<https://reactome.org/>), and hemostasis ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}) with specific involvement of Tie2 \[[@R11]\], Basigin-transmembrane glycoprotein signaling \[[@R12]\] ([Supplementary Figures 2](#SD1){ref-type="supplementary-material"} and [3](#SD1){ref-type="supplementary-material"}), CFH-mediated complement cascade, HTLF-mediated protein-ubiquitination, SPTLC3 mediated sphingolipid metabolism, and ZNF711-mediated RNA polymerase II transcription pathways were overexpressed in TKI-resistant cases.

![Hierarchical clustering of 13 CML samples (TKI-sensitive cases and TKI resistant cases) common between transcriptomics and CNV analysis were compared to control using the same filter criteria as for all CML cases and control at p=0.01](oncotarget-09-30385-g002){#F2}

![PCA plot between Cluster III (TKI-sensitive cases) and Cluster I+II (TKI resistant cases) at exonic-level using specific splicing index filter criteria \[(1.) Exon Splicing Index (linear) \< -4 or Exon Splicing Index (linear and exon expressed in atleast one condition) \>4; 2.) ANOVA Exon p value \< 0.001; Exon FDR p value \<0.001. 3.) Gene fold change (linear and expressed in both conditions) \< -5 or Gene fold change (linear) \> 5\], 0.01% coding-genes passed filter criteria](oncotarget-09-30385-g003){#F3}

Validation of array-based transcripts by differential expression analysis {#s2_5}
-------------------------------------------------------------------------

Down-regulated FOS, TGFβR2 and up-regulated TPX2 among all drug-treated CML cases as well as significantly up-regulated LAPTM4B, PIEZO2, ANGPT1, CFH, CD109 and HLTF molecule in TKI-resistant cases were validated in 23 Imatinib-treated CML cases. The samples were categorized on the basis of major molecular response (\>1% and not-detected BCR-ABL copies). FOS and TGFβR2 down-regulated in \~48% of all Imatinib-treated CML cases (Table [4a](#T4){ref-type="table"} and [4b](#T4){ref-type="table"}). While TPX2 was up-regulated in 21.73% Imatinib-treated cases with \>1% BCR-ABL copies and down-regulated or non-significant in most of the Imatinib-treated cases.

###### Validation of (array-based) FOS, TGFβR2, TPX2, LAPTM4B, PIEZO2, ANGPT1, CFH, CD109 and HLTF transcripts by differential expression analysis in \>1% and not detected %BCR-ABL 23 Imatinib-treated CML cases using beta actin and 18s ribosomal house-keeping gene as reference

                         Duration       %BCR-ABL       Treatment       FOS               TGFBR2          TPX2            CFH             PIEZO2          CD109           ANGPTI          LAPTM4B        HLTF
  ---------------------- -------------- -------------- --------------- ----------------- --------------- --------------- --------------- --------------- --------------- --------------- -------------- ---------------
  **CML-1 (CP-UT)**      6 mths         5.56           Imatinib        NS                UP (≥0.020)                     NS              UP (≥0.012)     NS              NS              UP (≥0.000)    UP (≥0.020)
  **CML2 (CP-UT)**       4 yrs          38.78          Imatinib        Down (≥0.020)     UP (≥0.041)     Down (≥0.020)   Down (≥0.020)   Down (≥0.020)   Down (≥0.020)   Down (≥0.020)   NS             Down (≥0.020)
  **CML-3 (CP-UT)**      6 mths         20.01          Imatinib        NS                NS              Down (≥0.040)   NS              UP (≥0.000)     NS              UP (≥0.030)     UP (≥0.000)    NS
  **CML6 (CP-UT)**       3 yrs          4.37           Imatinib        Down (≥0.020)     NS              NS              Down (≥0.033)   NS              NS              Down (≥0.036)   NS             NS
  **CML-7 (B-UT)**       6 mth          12.56          Imatinib        Down (≥0.031)     NS              NS              NS              UP (≥0.048)     NS              NS              UP (≥0.024)    NS
  **CML-9 (CP-UT)**      5 yrs          4.32           Imatinib        NS                Down (≥0.000)   NS              NS              UP (≥0.000)     NS              UP (≥0.000)     UP (≥0.000)    NS
  **CML12 (AP-UT)**      2 yrs          6.17           Imatinib        NS                NS              UP (≥0.020)     NS              NS              UP (≥0.020)     UP (≥0.041)     UP (≥0.011)    UP (≥0.000)
  **CML13 (AP-UT)**      2 yrs          3.65           Imatinib        NS                Down (≥0.029)   NS              UP (≥0.000)     NS              UP (≥0.023)     UP (≥0.031)     UP (≥0.000)    NS
  **CML14 (CP-UT)**      1 yrs          1.23           Imatinib        NS                Down (≥0.008)   NS              UP (≥0.031)     NS              UP (≥0.000)     UP (≥0.049)     UP (≥0.000)    NS
  **CML-16 (CP-UT)**     3 mths         0.03           Imatinib        NS                Down (≥0.011)   NS              NS              UP (≥0.020)     NS              UP (≥0.000)     UP (≥0.032)    NS
  **CML17 (CP-UT)**      3 mths         16.13          Imatinib        Down (≥0.036)     Down (≥0.036)   UP (≥0.000)     UP (≥0.000)     UP (≥0.000)     UP (≥0.034)     Down (≥0.036)   NS             UP (≥0.000)
  **CML29 (B-UT)**       3 yrs          11.74          Imatinib        NS                Down (≥0.046)   NS              NS              NS              NS              NS              NS             NS
  **CML31 (AP-UT)**      2 yrs          15.23          Imatinib        Down (≥0.039)     NS              UP (≥0.000)     UP (≥0.000)     UP (≥0.000)     UP (≥0.000)     UP (≥0.050)     NS             UP (≥0.000)
  **CML32 (B-UT)**       2 yrs          6.85           Imatinib        Down (≥0.029)     NS              UP (≥0.000)     UP (≥0.000)     UP (≥0.000)     UP (≥0.000)     UP (≥0.000)     NS             UP (≥0.000)
  **CML33 (B-UT)**       3 mths         126            Imatinib        Down (≥0.008)     Down (≥0.034)   NS              UP (≥0.030)     UP (≥0.028)     UP (≥0.033)     NS              NS             UP (≥0.008)
  **CML37 (CP-UT)**      3 yrs          3.38           Imatinib        NS                NS              Down (≥0.042)   NS              NS              NS              NS              NS             UP (≥0.011)
  **Percent -Up**                                                      **6.666666**      **6.666667**    **26.66667**    **46.66667**    **60**          **53.33333**    **53.33333**    **53.33333**   **46.66666**
  **Percent - Down**                                                   **40**            **46.66667**    **20**          **13.33333**    **6.666667**    **6.666667**    **13.33333**    **0**          **6.666666**
  **Sensitive Cases-**   **Duration**   **%BCR-ABL**   **Treatment**   **FOS**           **TGFBR2**      **TPX2**        **CFH**         **PIEZO2**      **CD109**       **ANGPTI**      **LAPTM4B**    **HLTF**
  **CML8 (CP-UT)**       6 yrs          Not detected   Imatinib        NS                NS              NS              NS              NS              NS              NS              NS             UP (≥0.000)
  **CML4 (CP-UT)**       5 yrs          Not detected   Imatinib        Down (≥0.038)     Down (≥0.038)   NS              Down (≥0.038)   NS              Down (≥0.038)   Down (≥0.049)   NS             Down (≥0.038)
  **CML5 (CP-UT)**       2 yrs          Not detected   Imatinib        NS                NS              Down (≥0.031)   Down (≥0.031)   Down (≥0.020)   Down (≥0.031)   Down (≥0.042)   NS             Down (≥0.031)
  **CML11 (CP-UT)**      3 yrs          Not detected   Imatinib        Down (≥0.047)     Down (≥0.047)   Down (≥0.047)   Down (≥0.047)   NS              Down (≥0.047)   Down (≥0.038)   NS             Down (≥0.047)
  **CML34 (CP-UT)**      4 yrs          Not detected   Imatinib        Down (≥0.036)     Down (≥0.036)   Down (≥0.036)   NS              NS              NS              NS              NS             Down (≥0.036)
  **CML10 (CP-UT)**      2 yrs          Not detected   Imatinib        Down (≥0.024)     Down (≥0.019)   NS              NS              NS              Down (≥0.021)   Down (≥0.041)   NS             NS
  **CML15 (CP-UT)**      3 yrs          Not detected   Imatinib        NS                NS              NS              NS              Down (≥0.038)   NS              NS              NS             NS
  **Percent -Up**                                                      **0**             **0**           **0**           **0**           **0**           **0**           **0**           **0**          **14.28571**
  **Percent - Down**                                                   **57.14285714**   **57.14286**    **42.85714**    **14.28571**    **6.666667**    **57.14286**    **57.14286**    **0**          **57.14285**

NS = Non-sensitive.

LAPTM4B (53.33% cases), PIEZO2 (60% cases), ANGPT1 (53.33% cases), CFH (46.66% cases), CD109 (53.33% cases) and HLTF (46.66% cases) molecule were up-regulated in \>1% BCR-ABL copies Imatinib-treated CML cases and 57.14%, 14.28%, 57.14%, 6.66%, 0%, 57.14%, HLTF, CFH, CD109, PIEZO2, LAPTM4B and ANGPT1 respectively down-regulated in not detected BCR-ABL copies (Table [4a](#T4){ref-type="table"} and [4b](#T4){ref-type="table"}).

Biobank genotyping of CML resistant cases {#s2_6}
-----------------------------------------

Axiom Biobank genotyping data was analyzed through automated Genotyping Console Software, which includes allele-calling algorithms and user-friendly visualization tools. All analyzed samples passed QC, and 99.571% was the average call rate. An explanation of the SNP metrics summary is provided in [Supplementary Table 4](#SD5){ref-type="supplementary-material"}. On the basis of gender, 69 samples were from male patients, and 27 samples were from female patients.

pLink software (<http://zzz.bwh.harvard.edu/plink/>) was used to perform a range of basic, large-scale analyses in a computationally efficient manner. Associations between individual SNPs and CML risk were assessed using p=0.001 and ORs \> 4.0 and 95% CIs derived from logistic regression models.

Seventeen SNPs reached genome-wide significance (p=0.001) for TKI-treated CML samples (2 SNPs on chromosome 1, 2 SNPs on chromosome 2, 1 SNP on chromosome 4, 1 SNP on chromosome 5, 4 SNPs on chromosome 6, 1 SNP on chromosome 12, 2 SNPs on chromosome 13, 2 SNPs on chromosome 16, 1 SNP on chromosome 20, and 1 SNP on chromosome 21) ([Supplementary Table 5a](#SD1){ref-type="supplementary-material"}). Furthermore, regional LD plot was generated for each query SNP (identified through pLink software) through SNAP Proxy search software using r2 threshold=0.8, a distance limit between query and proxy SNP=500, 1000 genomes pilot 1 data-set from the 1000 Genomes Project, which uses phased genotypes for 179 individuals from the HapMap CEU (Utah residents with Northern and Western European ancestry from the CEPH collection), YRI (Yoruba in Ibadan, Nigeria), and JPT+CHB (combined panel of Japanese in Tokyo, Japan and Han Chinese in Beijing, China) panels. From these analyses, rs239798 showed complete correlation with rs9475077, such that r2=1 at a maximum distance of 801 ([Supplementary Table 5b](#SD1){ref-type="supplementary-material"}). rs12057639 was correlated with rs1327107 (r2=0.934 at a distance of 1, 03, 649) ([Supplementary Table 5b](#SD1){ref-type="supplementary-material"}). Association plots for rs9475077 and rs12057639 are shown in [Supplementary Figure 4a](#SD1){ref-type="supplementary-material"} and [4b](#SD1){ref-type="supplementary-material"}. Importantly, both rsID239798 (Ch6:54940890) and rsID9475077 (Ch6:54941691) were associated with FAM83B. Hence, we validated rs239798 and rs9475077 with the Taqman genotyping protocol (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}, Table [5](#T5){ref-type="table"}) and identified similar allele frequency as observed through Axiom Biobank Array.

![With high-quality threshold the each sample is clustered on the basis of genotype call\
Here the cluster observed shows the presence of FAM-labelled allele-2 (C) in all samples in rs239798. The yellow spots are the negative controls.](oncotarget-09-30385-g004){#F4}

![With high-quality threshold the each sample is clustered on the basis of genotype call\
Here the cluster observed shows the presence of FAM-labelled allele-2 (A) in all samples in rs9475077. The yellow spots are the negative controls.](oncotarget-09-30385-g005){#F5}

###### Genotyping of rs2854344 and rs9475077 through unlabeled PCR primers and TaqMan® MGBprobes (FAM ™ and VIC® dye-labeled in 40X assay mix

  rs239798                                                                                                                                                                    
  ---------------- --------------------------------------------------- ------------------------ ------------------- ------------------- ------------------- ----------------- -------------
  CML              0.728395062                                         0.27160494               0.5617284           0.333333333         0.10493827          4.021168          0.044937
  Control          0.933333333                                         0.06666667               0.9                 0.066666667         0.03333333          19.40051          0
  **rs9475077**                                                                                                                                                               
  **Population**   **Allele 1 Frequency (Minor Allele Frequency-A)**   **Allele 2 Frequency**   **1/1 Frequency**   **1/2 Frequency**   **2/2 Frequency**   **Chi-Squared**   **P-Value**
  CML              0.282978723                                         0.71702128               0.1021277           0.361702128         0.53617021          2.775499          0.045747
  Control          0.033333333                                         0.96666667               0                   0.066666667         0.93333333          0.107015          0.743586

DISCUSSION {#s3}
==========

This study provides evidence to support that, in addition to the BCR-ABL translocation t(9;22) (q34;q11), specific gene abnormalities contribute to the transformation from CML-chronic phase (CML-CP) with no copy number aberrations (CNAs) to CML-blast crisis (CML-BC) in adult and pediatric CML \[[@R13]--[@R17]\]. In pediatric CML-BC of lymphoid origin, deletions in IKZF1, PAX5, and/or CDKN2A have been frequently reported \[[@R13], [@R14]\]. In adults, Hosoya *et al.* performed genome-wide screening of DNA in a total of 55 CML patients at different stages using a high-resolution array-based comparative genomic hybridization technique \[[@R18]\]. They identified losses in 2q26.2-q37.3, 5q23.1-q23.3, 5q31.2-q32, 7p21.3-p11.2, 7q31.1-q31.33, 8pter-p12(p11.2), 9p, and 22q13.1-q13.31 and gains in 3q26.2-q29, 6p22.3, 7p15.2-p14.3, 8p12, 8p21.3, 8p23.2, 8q24.13-q24.21, 9q, 19p13.2-p12, and 22q13.1-q13.32 in chronic phase and reported that these alterations occurred at a higher frequency in AP and blast crisis \[[@R18]\]. Another study by Brazma *et al.* \[[@R19]\] reported losses at 1p36, 5q21, and 9p21 and gains at 1q, 8q24, 9q34, 16p, and 22q11 after genome-wide screening at a resolution of 1 Mb among 54 samples at different stages of CML together with 12 CML cell lines. Furthermore, Mullighan *et al.* \[[@R20]\] found higher CNAs in CML-AP and CML-BC of lymphoid origin (1.14 and 7.8, respectively) compared to CML-CP (0.47) using SNP array analysis of 34 adult CML cases \[[@R20]\].

Compared to the references described above \[[@R18]--[@R20]\] in undetectable-BCR-ABL-TKI-sensitive group, we similarly observed the previously reported loss of 7p15.2-HOXA9, HOXA11, and HOXA13. In BCR-ABL-dependent/independent TKI-non-sensitive group, we also observed the previously reported loss of 1p36 (TNFRSF14, PRDM16), 2q31.1 (HOXD13, HOXD11), 5q32(PDGFRB), and 7q31.2 (MET) and gain of 9q34.11-q34.2 (FNBP1, ABL1, NUP214, TSC1, and RALGDS genes (Table [2b](#T2b){ref-type="table"} and [2c](#T2c){ref-type="table"}). Hence, through above references and our study, we conclude that CNAs were absent in CML-CP-New and CML-CP-UT-TKI-sensitive cases. However, these reported variations were relatively common in samples at progressed stages and TKI-non-sensitive cases. These observations support the notion that the BCR-ABL fusion protein is sufficient to induce CML, but additional genomic changes are required for disease progression and play important roles in resistance to TKI \[[@R13]--[@R17]\].

Further, genome-wide transcriptomics have also provided insight into the mechanisms of distinction between CP and BC, progression and resistance of CML on the whole blood of different phases of CML-patients, cell lines, leukemia stem cells, and normal stem and progenitor cell populations \[[@R6], [@R10], [@R17]\] Radich *et al*. \[[@R6]\] showed an association of decreased expression of Jun B and Fos with other deregulated pathways with early accelerated phase and identified 6 genes (NOB1, DDX47, IGSF2, LTB4R, SCARB1, and SLC25A3) that discriminated CP from BC \[[@R6]\]. Later, Wang *et al.* \[[@R17]\] reported over-expression of early erythroid-related factors \[[@R9], [@R21]\] transcription factors and activation of proliferative markers like ERK/MAPK, JAK-STAT, and ErbB pathways in K562 cell line \[[@R22]\]. Gerber *et al.* \[[@R10]\] performed genome-wide transcriptome analysis of CML leukemia stem cells and normal stem and progenitor cell populations using exon arrays. They identified 97 genes that were differentially expressed in CML versus normal stem and progenitor cells. These included significantly up-regulated cell surface genes and genes involved in oxidative metabolism, DNA repair pathways and the activation of inflammatory cytokines. They also observed down-regulation of pro-differentiation and TGF-β/BMP signaling pathways \[[@R10]\]. However, methylation and down-regulation of 897 genes including tumor-suppressor genes or regulators of cell proliferation were observed during disease progression, i.e., conversion of CP to AP/Blast \[[@R23]\].

We also identified up-regulation of highly significant proliferative (24 genes in the RB pathway, ARG1 and CDK1), cell cycle (6 genes involved in G1 to S cell cycle control and 12 genes involved in Mitotic G1-G1/S phases), replicative (8 genes involved in DNA replication) and DNA repair markers (9 genes involved in DNA repair) and down-regulation of several genes related to the immune system (10 genes involved in allograft rejection and 12 genes involved in the Vitamin D receptor pathway), TCR signaling, TGF-beta signaling (FOS, FOSB, TGFBR2, ETS1, JUNB, and LIMK2) and chemokine signaling pathway (CCR6, CCR4, CCR7, CX3CR1, XCL1, CXCL16, JAK3, LYN, ITK, and TIAM1) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) in all drug-treated CML samples when compared against control.

At the exon level, high splicing index affected the dysregulation of normal cellular processes in drug-treated CML cases, including up-regulation of Myeloperoxidase (MPO)-induced neutrophil degranulation affecting the innate immune system \[[@R24]\], TPX2 up-regulation, suggesting inhibition of TP53 transcriptional activity \[[@R25], [@R26]\], and TYMS, suggesting CML cells are more within the G1/S transition through more formation of TMP and dihydrofolate. Overall, these three factors affected the up-regulation of cell cycle (Reactome Analysis). Further, down-regulation of SKAP1 (Src Kinase Associated Phosphoprotein 1), ITK and TGFBR2 and FOS in CML cases led to down-regulation of the TCR signaling and immune system pathways Additionally, the Src-family kinases (SFKs) have been implicated in BCR-ABL signaling and in the progression of CML \[[@R27]\]. ITK and FOS are involved in the down-regulation of TCR signaling and immune system, respectively, as reported by \[[@R6], [@R10]\]. On validation in more samples, FOS and TGFBR2 were down-regulated in \~ fifty percent cases and were independent of major molecular response. Contrarily, TPX2 was up-regulated in cases with \>1% BCR-ABL copies further validate suppression of TP53 transcriptional activity in resistance \[[@R25], [@R26]\].

Further, CML-resistant versus -sensitive cases at the exon level, due to high splicing index, nine genes were differentially expressed. Out of which six genes were further validated in additional resistant (\>1% BCR-ABL copies in CML-CP-UT, CML-AP-UT, CML-B-UT,) and sensitive (undetectable levels BCR-ABL copies in CML-CP-UT) cases. These genes showed specific involvement of Tie2 ([Supplementary Figures 1](#SD1){ref-type="supplementary-material"} and [2](#SD1){ref-type="supplementary-material"}) and Basigin-transmembrane glycoprotein ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}) in Imatinib-resistant CML cases as reported previously \[[@R11], [@R12]\]. Tie-2 receptor tyrosine kinase and its ligand ANGPT1 are involved in CML progression or resistance \[[@R28]\]. Basigin also plays important role in tumor invasion, as it is co-expressed in the presence of high lactate and has been reported as a poor prognostic indicator in GIST \[[@R35]\] and imatinib-resistant indicator in CML cells \[[@R29]\]. Amplification of LAPTM4B, which contributes to chemotherapy resistance and recurrence of breast cancer \[[@R30], [@R31]\] and other solid tumors \[[@R32]\] was over-expressed in our TKI-resistant CML cases. Additionally, inactive EGFR complexes with LAPTM4B recruits Sec5exocyst sub complex which binds to autophagy inhibitor and activates autophagy \[[@R33]\]. Up-regulation of HLTF is associated with tumor progression in hypopharyngeal and cervical cancers \[[@R34], [@R35]\] was over-expressed in our TKI-resistant CML cases. Recently, Cipolla *et al* \[[@R36]\] suggested that HLTF repairs DNA damage by acting as a ubiquitin ligase caused by drug-induced reactive oxygen species, leading to resistance \[[@R36]\] and also modulates lysosomal autophagy \[[@R37]\]. CD109 regulates TGF-β receptor endocytosis and degradation to inhibit TGF-β signaling \[[@R38]\] and over-expression of CD109 in Imatinib resistant cases may further down-regulate TGF- β signaling. CFH co-factor for complement factor 1 inhibits C3 activation cascade in alternative pathway by promoting cleavage of C3b to iC3b-over-expression has been reported in cutaneous squamous cell carcinoma cells \[[@R39]\]. Expression of CFH help in immune escape and it has been documented in malignant ovarian and bladder cancers \[[@R40]\]. CFH also controls the stemness of liver cancer cells \[[@R41]\]. PIEZO2 which has been proposed as biomarker for CML stem cells \[[@R8]\] was also over-expressed in our Imatinib resistant cases.

Analysis of CML patients in the chronic phase and under treatment (CML-CP-UT) with BCR-ABL10-77.02% as identified through the genotyping array, which has been designed for a broad range of applications to give us complete flexibility both for identification of genotypic markers and to explore the complexity of diseases \[[@R42], [@R43]\], we found that rsID239798 (Ch6:54940890) and rsID9475077 (Ch6:54941691) were associated with FAM83B. FAM83B is a proto-oncogene involved in the epidermal growth factor receptor (EGFR) signaling pathway and activates both the EGFR itself and downstream RAS/MAPK and PI3K/AKT/TOR signaling cascades \[[@R44]--[@R46]\]. Both the rsIDs are missense mutations and show a minor allele frequency of C=0.2895/1450 (rsID239798; lysine (K) to Threonine (T) transition at position 640) and A=0.2893/1449 (rsID9475077; threonine (T) to Asparagine (N) transition at position 907) as established by 1000 Genome Project \[[@R47]\]. Grant \[[@R48]\] also suggested a role for FAM83A and FAM83B in therapeutic resistance to TKI \[[@R49]\].

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

All the samples were obtained after informed consent, and the study was approved by the Institutional Ethics Committee, King George\'s Medical University. All experiments have been performed in accordance with relevant guidelines and regulations.

Patients and sample preparation {#s4_2}
-------------------------------

We collected peripheral blood samples from 4 healthy volunteers and 70 clinically diagnosed CML patients, which included treated and new chronic phase (CML-CP-UT and CML-CP-New), treated CML-accelerated phase (CML-AP-UT), and treated fresh blast phase (CML-B-UT and CML-B-New) samples from the Department of Clinical Hematology, King George\'s Medical University, Lucknow, India. All CML samples displayed a myeloid phenotype. More than 90% of patient cells were Philadelphia chromosome-positive (Ph), and blast crisis was characterized by \>30% or \>50% blasts and promyelocytes in peripheral blood or bone marrow, respectively \[[@R50]\].

All patients (Table [6](#T6){ref-type="table"}) were treated with Imatinib alone or in combination with Hydrea/Hydroxyurea. Importantly, when patients failed to achieve time-dependent molecular targets, we switched to nilotinib or high-dose Imatinib. Clinical outcomes included molecular response based on BCR-ABL. Additionally, because patients were from a remote area, the samples used in the study were collected on dates other than the date of disease initiation or the date on which BCR-ABL expression was assessed.

###### Chronic myeloid leukemia - clinical presentation showing different phases without (Chronic Phasenew; CP-new and Blast new; B-new) and with (Chronic Phase under treatment; CP-UT, accelerated phase under treatment; AP-UT and Blast Phase under treatment; B-UT ) treatment for the samples being processed for copy number variations and transcriptomics analysis

  Chronic myeloid Leukemia-Chronic Phase New (CML-CP-New)                                                                                                                                                                                                                                                                                                                
  ---------------------------------------------------------------------------- --------------- ------------- ---------------------------- ------------------------ ---------------------------- -------------------- ----------------------------------------------------------------------------------- ------------------------------- ------------------------------- -------------------------------------------------------------------------------------------------
  1                                                                            9               46/M          28-05-2014                   New                      28-05-2014                   28-05-2015           Imatinib                                                                            28-05-2014                      100                             \-
  2                                                                            10              20/M          28-05-2014                   New                      28-05-2014                   30-03-2015           Imatinib                                                                            28-05-2014                      120                             \-
                                                                                                                                                                                                                                                                                                         06-02-2015                      0.95                            \-
  3                                                                            30              22/M          12-06-2014                   New                      24-06-2014                   24-06-2014           Imatinib                                                                            24-06-2014                      100                             \-
                                                                                                                                                                                                                                                                                                         30-09-2014                      12.65                           
  4                                                                            73              50/M          22-04-2015                   New                      25-04-2015                   29-04-2015           Imatinib                                                                            25-04-2015                      73.8                            \-
  5                                                                            83              70/M          27-04-2015                   New                      18-04-2015                   01-05-2015           Imatinib                                                                            18-04-2015                      77.02                           \-
  **Chronic myeloid Leukemia-Chronic Phase Under Treatment (CML-CP-UT)**                                                                                                                                                                                                                                                                                                 
                                                                               **Sample No**   **Age/Sex**   **Sample collection date**   **Time of Assessment**   **Date disease initiated**   **Follow up date**   **Treatment**                                                                       **Date of BCR-ABL detection**   **BCR-ABL%**                    **Comments based on BCR-ABL**
  6                                                                            2               50/M          22-05-2014                   4 yrs                    10-06-2010                   20-03-2014           Droxygel (Antacid), Unidrea and Imatinib                                            14-02-2013                      100%                            Initially with Droxygel (Antacid), Unidrea and later with Imatinib sensitive
                                                                                                                                                                                                                                                                                                         20-03-2014                      not detected                    
  7                                                                            4               14/M          22-05-2014                   10 months                04-07-2013                   20-04-2015           Imatinib                                                                            15-07-2013                      100                             Imatinib sensitive
                                                                                                                                                                                                                                                                                                         06-09-2014                      Not detected                    
                                                                                                                                                                                                                                                                                                         18-03-2015                      81.88                           
  8                                                                            6               24/M          22-05-2014                   7 months                 21-11-2013                   22-06-2015           Imatinib                                                                            21-11-2013                      75                              Imatinib sensitive
                                                                                                                                                                                                                                                                                                         17-06-2014                      0.09                            
  9                                                                            7               41/M          22-05-2014                   7.2 yrs                  29-03-2007                   21-05-2015           Imatinib                                                                            28-02-2007                      100%                            Imatinib sensitive
                                                                                                                                                                                                                                                                                                         22-07-2014                      not Detected                    
  10                                                                           11              33/F          28-05-2014                   4.2 yrs                  21-05-2014                   23-04-2015           Hydab and Imatinib                                                                  21-04-2010                      97.54                           
                                                                                                                                                                                                                                                                                                         21-05-2014                      not Detected                    Hydab and Imatinib sensitive
  11                                                                           13              50/M          29-05-2014                   7.1 yrs                  26-04-2007                   06-07-2015           Droxygel (Antacid), Unidrea and Imatinib                                            20-02-2014                      30                              Droxygel (Antacid), Unidrea and Imatinib sensitive
                                                                                                                                                                                                                                                                                                         12-03-2015                      0.1                             
  12                                                                           16              30/M          29-05-2014                   10 months                23-03-2015                   19-03-2015           Imatinib                                                                            23-05-2014                      43.2                            Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         19-03-2015                      35                              
  13                                                                           20              33/F          05-06-2014                   1 month                  21-05-2014                   05-06-2014           Imatinib                                                                            21-05-2014                      97.54                           NA
  14                                                                           21              60/M          05-06-2014                   3.8 yrs                  09-09-2010                   11-06-2015           Droxygel (Antacid), Unidrea and Imatinib                                            14-11-2013                      75                              Droxygel (Antacid), Unidrea and Imatinib-sensitive
                                                                                                                                                                                                                                                                                                         31-07-2014                      0.11                            
  15                                                                           23              40/M          05-06-2014                   2.4 yrs                  24-02-2012                   05-06-2014           Unidrea and Imatinib, Nilotinib                                                     31-07-2013                      28.35                           Unidrea and Imatinib, Nilotinib-non-sensitive (TKI non sensitive)
                                                                                                                                                                                                                                                                                                         13-05-2014                      11.9                            
                                                                                                                                                                                                                                                                                                         16-02-2015                      16.53                           
  16                                                                           24              26/F          05-06-2014                   8.5 yrs                  05-01-2006                   21-05-2015           Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib   24-04-2014                      30                              Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         21-05-2015                      15.85                           
  17                                                                           26              32/M          05-06-2014                   2.1 yrs                  10-05-2012                   22-09-2014           Imatinib                                                                            26-03-2012                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         10-05-2014                      13.6                            
  18                                                                           36              23/M          03-07-2014                   6.10 yrs                 08-09-2007                   07-05-2015           Hydab and Imatinib                                                                  20-02-2010                      30                              Hydab and Imatinib-sensitive
                                                                                                                                                                                                                                                                                                         30-10-2014                      not detected                    
  19                                                                           43              27/M          10-07-2014                   7 yrs                    21-07-2007                                        Initially Hydroxyurea and Imatinib                                                  23-02-2012                      55.89                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         17-06-2014                      11.18                           
                                                                                                                                                                                                                                                                                                         14-03-2015                      0                               
  20                                                                           48              33/M          31-07-2014                   10.4 yrs                 16-03-2004                   18-09-2014           Initially Hydroxyurea and since December 2004 Imatinib                              01-10-2004                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         07-03-2013                      60                              
                                                                                                                                                                                                                                                                                                         05-09-2013                      41.1                            
                                                                                                                                                                                                                                                                                                         03-09-2013                      41.41                           
                                                                                                                                                                                                                                                                                                         29-05-2014                      9.94                            
  21                                                                           50              21/M          31-07-2014                   4.3 yrs                  01-04-2010                   18-09-2014           Imatinib                                                                            20-11-2013                      23.3                            Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         13-08-2014                      10.12                           
  22                                                                           51              60/M          31-07-2014                   25 year                                                                    Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib   12-05-2013                      30                              Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         11-06-2014                      8.98                            
  23                                                                           52              40/M          31-07-2014                   4.3 yrs                  01-04-2010                   31-07-2014           Imatinib                                                                            10-04-2010                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         01-07-2014                      18                              
  24                                                                           53              24/M          08-01-2015                   3.1 yrs                  08-12-2011                   08-01-2015           Imatinib                                                                            08-12-2011                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         22-02-2015                      17.23                           
  25                                                                           54              28/M          06-02-2015                   4.4 yrs                  15-10-2010                   22-12-2014           Imatinib                                                                            15-05-2014                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         06-11-2014                      40.4                            
  26                                                                           55              60M           06-02-2015                   3 months                 02-12-2014                   01-05-2015           Hydroxyurea, Zyloric and Imatinib                                                   02-12-2014                      98.47                           Hydroxyurea, Zyloric and Imatinib-non- sensitive
                                                                                                                                                                                                                                                                                                         01-05-2015                      9.75                            
  27                                                                           56              43F           09-02-2015                   1.0 yr                   29-02-2014                   24-03-2015           Hydroxyurea, Zyloric and Imatinib                                                   29-02-2014                      89.5                            Hydroxyurea, Zyloric and Imatinib non- sensitive
                                                                                                                                                                                                                                                                                                         24-03-2015                      1.2                             
  28                                                                           57              42F           09-02-2015                   7 months                 22-07-2014                   22-04-2015           Hydroxyurea, Zyloric and Imatinib                                                   22-07-2014                      67.45                           Hydroxyurea, Zyloric and Imatinib non- sensitive
                                                                                                                                                                                                                                                                                                         22-04-2015                      8                               
  29                                                                           58              32/F          09-02-2015                   9 months                 12-04-2015                   12-04-2015           Hydroxyurea, Zyloric and Imatinib                                                   12-04-2015                      58.75                           Hydroxyurea, Zyloric and Imatinib non- sensitive
                                                                                                                                                                                                                                                                                                         12-04-2015                      9.8                             
  30                                                                           59              15/M          01-04-2015                   3 months                 10-12-2014                   13-04-2015           Hydroxyurea, Zyloric and Imatinib                                                   11-12-2014                      15.75                           Hydroxyurea, Zyloric and Imatinib non- sensitive
                                                                                                                                                                                                                                                                                                         29-04-2015                      9.75                            
  31                                                                           60              29/F          09-04-2015                   4.5 yrs                  28-12-2010                                        Imatinib                                                                            08-04-2011                      18                              Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         24-02-2015                      16                              
  32                                                                           61              26/F          09-04-2015                   9.4 yrs                  18-12-2005                                        Imatinib                                                                            08-04-2011                      18%                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         24-02-2014                      BCR-ABL positive in 200 cells   
  33                                                                           63              37/M          09-04-2015                   7 months                 21-08-2014                   09-04-2015           Imatinib                                                                            21-08-2014                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         09-04-2015                      80                              
  34                                                                           65              43/M          20-04-2015                   7.9 yrs                  29-06-2007                   22-04-2015           Imatinib                                                                            24-06-2014                      18.95                           Imatinib non-sensitive, however, nilotinib sensitive
                                                                                                                                                                                                                                                                                                         22-04-2015                      4.63                            
  35                                                                           66              30/F          20-04-2015                   4.4yrs                   15-05-2010                   22-12-2014           Imatinib                                                                            15-05-2014                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         06-01-2015                      40.4                            
  36                                                                           67              52/M          16-04-2015                   6.1 yrs                  21-02-2009                   01-06-2015           Initially Hydab, Uridrea and since october 2012 Imatinib                            15-04-2014                      20                              Initially Hydab, Uridrea and since october 2012 Imatinib-non-sensitive
                                                                                                                                                                                                                                                                                                         01-06-2015                      18.63                           
  37                                                                           68              28/M          16-04-2015                   4 months                 01-11-2014                   08-06-2015           Imatinib                                                                            22-09-2014                      45.2                            Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         22-04-2015                      16.1                            
  38                                                                           71              52/M          16-04-2015                   8.1 yrs                  21-02-2007                   21-06-2015           Initially Hydab, Uridrea and since october 2012 Imatinib                            15-04-2014                      20                              Initially Hydab, Uridrea and since october 2012 Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         22-06-2015                      8.63                            
  39                                                                           75              20/M          27-04-2015                   2.1 yrs                  02-03-2013                   02-05-2015           Initially Hydab, Uridrea and since march 2013 Imatinib                              02-03-2013                      100                             Initially Hydab, Uridrea and since march 2013 Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         01-04-2015                      20                              
  40                                                                           77              25/M          27-04-2015                   7.2 yrs                  19-02-2008                   03-05-2015           Imatinib                                                                            19-02-2008                      80                              Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         03-04-2015                      8                               
  41                                                                           78              30/F          27-04-2015                   3.1 yrs                  21-03-2013                   03-05-2015           Imatinib                                                                            28-10-2013                      74.91                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                                                         10                              
  42                                                                           79              45/M          27-04-2015                   2.3 yrs                  17-01-2013                   27-04-2015           Imatinib                                                                            10-01-2013                      110                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         04-03-2015                      39.09                           
  43                                                                           80              26/M          27-04-2015                   3.2 yrs                  10-02-2012                   03-05-2015           Imatinib                                                                            10-02-2012                      80                              Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         03-04-2015                      29                              
  44                                                                           81              26/F          27-04-2015                   2.6 yrs                  25-10-2012                   03-05-2015           Imatinib                                                                            25-10-2012                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         03-04-2015                      31.02                           
  45                                                                           84              23/M          27-04-2015                   8 yrs                    26-04-2007                   27-04-2015           Imatinib                                                                            10-12-2014                      20                              
                                                                                                                                                                                                                                                                                                         27-03-2015                      8                               
  46                                                                           85              30/M          27-04-2015                   9.7yrs                   13-09-2005                   03-05-2015           Hydab and Imatinib                                                                  08-07-2005                      110                             Hydab and Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         02-02-2015                      13.12                           
  47                                                                           87              45/F          08-06-2015                   2.9 yrs                  14-09-2011                   08-06-2015           Imatinib                                                                            01-07-2015                      86                              Imatinib non-sensitive
  48                                                                           88              48/M          08-06-2015                   4.8 yrs                  28-10-2010                   08-06-2015           Imatinib                                                                            17-07-2014                      30                              Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         13-05-2015                      10                              
  49                                                                           89              25/M          08-05-2015                   8 months                 23-08-2014                   08-06-2015           Imatinib                                                                            23-08-2014                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         24-03-2015                      2                               
  50                                                                           91              66/F          08-06-2015                   6 months                 10-11-2014                   08-06-2015           Imatinib                                                                            10-09-2014                      38.52                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         22-04-2015                      26.1                            
  51                                                                           93              60/M          08-06-2015                   11 months                17-07-2014                   08-06-2015           Imatinib                                                                            14-05-2014                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         11-03-2015                      70.13                           
  **Chronic Myeloid Leukemia-Accelerated Phase-Under Treatment (CML-AP-UT)**                                                                                                                                                                                                                                                                                             
                                                                               **Sample No**   **Age/Sex**   **Sample collection date**   **Time of Assessment**   **Date disease initiated**   **Follow up date**   **Treatment**                                                                       **Date of BCR-ABL detection**   **BCR-ABL%**                    **Comments based on BCR-ABL**
  52                                                                           1               35/M          22-05-2014                   1.8 yrs                  20-09-2012                   30-03-2015           Imatinib                                                                            30-08-2012                      26                              Imatinib non-sensitive
  53                                                                           22              40/M          05-06-2014                   5.2 yrs                  02-04-2009                   18-06-2014           Hydab and Imatinib                                                                  17-11-2013                      39.07                           Hydab and Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         05-08-2014                      20.11                           
  54                                                                           32              27/F          12-06-2014                   15 yrs                   02-06-1999                   30-03-2015           Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib   13-07-2014                      55.63                           Initially treated with Myeleron, Hydab irocos, Zyloric since may 2005 on Imatinib-non-sensitive
                                                                                                                                                                                                                                                                                                         17-11-2014                      35.37                           
                                                                                                                                                                                                                                                                                                         30-03-2015                      26.93                           
  55                                                                           33              20/M          28-06-2014                   2 yrs                    19-07-2012                   18-06-2015           Imatinib                                                                            24-07-2012                                                      Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         27-06-2014                      12.18                           
                                                                                                                                                                                                                                                                                                         14-03-2015                      0                               
  56                                                                           35              28/F          03-07-2014                   6.3 yrs                  03-04-2008                   03-07-2014           Imatinib                                                                            24-07-2010                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         13-04-2013                      0.02                            
                                                                                                                                                                                                                                                                                                         03-07-2014                      8.56                            
  57                                                                           37              27/F          03-07-2014                   8 months                 19-12-2013                   04-06-2015           Imatinib                                                                            01-04-2013                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         03-07-2014                      50                              
  58                                                                           38              60/M          03-07-2014                   1.5 yrs                  21-02-2013                   13-03-2014           Imatinib                                                                            29-03-2013                      79.01                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         24-06-2014                      35.12                           
  59                                                                           62              42/M          09-04-2015                   4.4 yrs                  04-11-2010                   09-04-2015           Uridrea, Imatinib and since February 2014 Nilotinib                                 06-06-2014                      14.96                           Uridrea, Imatinib was non-sensitive but Nilotinib was TKI-non-sensitive
                                                                                                                                                                                                                                                                                                         22-06-2015                      4.03                            
  60                                                                           69              40/F          16-04-2015                   3 months                 29-12-2014                   13-04-2015           Imatinib                                                                            04-11-2014                      14.08                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         29-04-2015                      9.75                            
  61                                                                           70              30/M          16-04-2015                   1.0 year                 01-04-2014                   22-04-2015           Imatinib and december 2014 nilotinib                                                10-01-2015                      20                              Imatinib and Nilotinib sensitive
                                                                                                                                                                                                                                                                                                         22-04-2015                      1.63                            
  62                                                                           72              45/M          16-04-2015                   6 months                 29-10-2014                   08-06-2015           Imatinib and june 2015 Nilotinib                                                    16-10-2014                      25.19                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         01-05-2015                      5.45                            
  63                                                                           86              49/M          27-04-2015                   5 months                 11-12-2014                   08-06-2015           Imatinib and march 2015 Nilotinib                                                   25-11-2014                      18.04                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         01-05-2015                      2.45                            
  **Chronic Myeloid Leukemia-Blast Phase New (CML-BP-New)**                                                                                                                                                                                                                                                                                                              
                                                                               **Sample No**   **Age/Sex**   **Sample collection date**   **Time of Assessment**   **Date disease initiated**   **Follow up date**   **Treatment**                                                                       **Date of BCR-ABL detection**   **BCR-ABL%**                    **Comments based on BCR-ABL**
  64                                                                           14              35/F          29-05-2014                   New                      25-05-2014                   04-05-2015           Imatinib                                                                            09-06-2014                      85.56                           
  65                                                                           19              28/M          29-05-2014                   New                      15-05-2014                   22-12-2014           Imatinib                                                                            15-05-2014                      100                             Imatinib non-sensitive switched to nilotinib
  66                                                                           34              24/M          12-06-2014                   New                      20-06-2014                   22-07-2015           Imatinib and since February 2015 Nilotinib                                          20-06-2014                      35.63                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         27-11-2014                      95.37                           
  67                                                                           8               24/M          22-05-2014                   8 months                 26-09-2013                   15-05-2014           Imatinib                                                                            26-09-2013                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         20-06-2014                      26.89                           
  68                                                                           29              35F           05-06-2014                   1 month                  04-05-2014                                        Imatinib                                                                            04-05-2014                      89.12                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         01-08-2014                      15.89                           
  69                                                                           47              48/M          17-07-2014                   3 months                 17-07-2014                   29-04-2015           Imatinib and 29-05-2014 Uridrea                                                     27-07-2014                      40.12                           Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         29-10-2014                      32.45                           
  70                                                                           49              15/M          31-07-2014                   1.4 yrs                  09-05-2013                   11-05-2015           Imatinib                                                                            06-03-2013                      100                             Imatinib non-sensitive
                                                                                                                                                                                                                                                                                                         30-06-2014                      not detected                    

Whole blood collected from 70 patients enrolled in this study were subjected to DNA and RNA extraction using QIAamp DNA mini kit (Qiagen, Hilden, Germany) and Trizol, respectively. The quality and quantity of DNA was checked both using a Quawell- spectrophotometer (Quawell Technology Inc., San Jose, CA 95161-2738) and a QubitBR-Fluorimeter (Agilent, Santa Clara, CA, USA). DNA samples with an absorption ratio (A260/A280) greater than 1.9 was considered for further CNV analysis using the Molecular Inversion based probe array (MIP-based array). RNA quantity and purity were determined by using the Samples with purity ratios (A260/A280) between 1.80 and 2.00 were considered for further analyses. Formaldehyde agarose gel were used to check the integrity of the extracted RNA; only samples with a 2:1 ratio of the 18S and 28S ribosomal RNAs were used for further transcriptomic analysis using the human transcriptome array 2.0 \[[@R51], [@R52]\].

Molecular inversion probe (MIP)-based oncoscan array hybridization {#s4_3}
------------------------------------------------------------------

Using the MIP-based Oncoscan array, 34 CML (out of 70 CML) and 5 control samples (one male, two females, and kit-derived positive and negative controls) were processed for CNV profiling using 12 ng/μL DNA per sample. According to the recommended protocol, the chips were processed and scanned through GENECHIP Scanner-7G (Affymetrix, CA) for identification of copy number and somatic mutation variations as reported previously \[[@R51]\]. Further, the OSCHP file generated through Oncoscan Console Software (Biodiscovery, Inc., CA USA) was analyzed via Tumor Scan (TuScan) and BioDiscovery\'s SNP-FASST2 algorithm using the Nexus Express for Oncoscan software version 7.5 (Biodiscovery, Inc., CA USA). The TuScan algorithm creates segmentation to differentiate between adjacent clusters of probes and determines copy number variations. The BioDiscovery\'s SNP-FASST2 algorithm, a proprietary variation of a Hidden Markov Model (HMM), is used to identify allelic event calls.

Human transcriptome array 2.0 hybridization {#s4_4}
-------------------------------------------

For transcriptomics, we processed 35 CML samples (out of 70 CML-samples) and 4 control samples. The CEL files were generated by processing 500 ng of total RNA on Affymetrix HTA 2.0 arrays according to the manufacturer\'s recommendations (Affymetrix, Santa Clara, Calif) and were scanned through GENECHIP Scanner-7G (Affymetrix, CA) \[[@R52]\]. The CEL files generated by these arrays were converted into rma-gene-ful.chp and. rma-alt-splice-dabg.chp files through Affymetrix Expression Console™ Software (version 1.3). The data was then analyzed through Transcriptome Analysis Consolev3.0. After running ANOVA, multi-testing correction was performed using Benjamini-Hochberg Step-Up FDR-controlling procedure for all expressed genes and expressed PSRs/Junctions (i.e., expressed in at least one condition). By default, the alpha level was set at 0.05 in the false discovery rate field.

Biobank genotyping array hybridization {#s4_5}
--------------------------------------

Axiom Biobank genotyping arrays was used to genotype 65 CML-TKI-treated CML cases- (out of 70 CML-samples) and 30 control samples ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Out of 65 cases, 19 new samples-Imatinib treated (CML-CP-UT) with BCR-ABL ranging from 10 to 77.02% (numbered 16, 50, 52-54, 60, 61, 66, 67, 75-82, 84, 85 and 88) were included in the study but were not processed for CNVs and Transcriptomics. The experiment was conducted as recommended by the manufacturer\'s protocol. All processed samples passed dish quality control (DQC), quality control call rate (QC CR) and plate quality control (QC). Average quality control (QC) call rate for the passing samples was 99.571.

REAL TIME SNP genotyping {#s4_6}
------------------------

We designed unlabeled PCR primers and TaqManMGBprobes (FAM and VIC dye-labeled) in 40X assay mix (Assays-by-DesignSM Service for SNP Genotyping Assays) to genotype rs2854344 and rs9475077. Alleles were scored in each well using TaqMan Genotyping Master Mix and 20 ng of specific genomic DNA following the universal thermal cycling parameters per the recommended protocol. Each sample was processed in triplicate, and a negative control was also processed for real-time analysis with every 96-well format assay. The raw data were obtained using ABI Step OnePlus Real-Time PCR System and were analyzed through TaqMan Genotype software. The genotype call was evaluated with a threshold quality value=0.94.

BCR-ABL transcript determination {#s4_7}
--------------------------------

For the quantitative detection and differentiation of BCR-ABL fusion gene transcripts major (M), minor (m), and micro (μ) in peripheral blood samples from CML patients, TRUPCR BCR-ABL REAL TIME PCR KIT was used with a real-time PCR system (ABI Step one plus). This kit is designed according to the "Europe Against Cancer" (EAC) and Guidelines for the measurement of BCR-ABL transcripts in CML patients with the updated international recommendations. It has a two-step protocol in which total RNA is reverse-transcribed, and the generated cDNA is amplified by PCR using a pair of specific primers and a specific internal double-dye probe for BCR-ABL (major, minor, and micro) and ABL. A standard curve was plotted against a known number of copies of BCR-ABL 1 and ABL1. Normalized copy number (NCN) was calculated using the following formula: NCN(%)= (BCR-ABL CN/ABL1 CN)^\*^100.

Expression analysis of selected genes using quantitative real-time PCR {#s4_8}
----------------------------------------------------------------------

Comparative relative expression of FOS, TGFBR2, TPX2, LAPTM4B, HLTF, CFH, PIEZO2, CD109, ANGPT1 against β actin and 18s ribosomal reference gene were measured by real-time PCR (RT-PCR) in 23 CML and 8 control samples. The RT-PCR amplifications were carried out using a ABI Stepone RT-PCR in a final volume of 20 μl containing 0.5 μl normalized cDNA, 10 pmol of each primer and 10 μl SYBR green master mix together with a negative control with no template by following RT-PCR steps; activation step at 95 °C for 5 min, followed by 40 cycles of: 15 s at 95 °C, 15 s at the Tm specific for the primer pairs used, and 35 s at 72 °C with a single fluorescence measurement. After the amplification phase, a melting curve cycle was set at 95 °C for 5 s, 67 °C for 1 min with acquisitions 5 per °C from 97 to 65 °C and a continuous measurement was performed to confirm later about the amplification of a single product. RT-PCR was repeated twice for each sample in triplicates. The crossing point, Ct values was acquired for both the target and reference gene using ABI Stepone RT-PCR software. The relative level of each transcript in different tissue was calculated by normalization of the value with the corresponding reference and compared among them using Ct values for tumor cDNA as positive calibrator. Comparison of relative expression level of each transcript was analyzed by REST 2009 software with 2000 time iterations (<http://www.REST.de.com>).

CONCLUSIONS {#s5}
===========

The highly significant down-regulation of STAT6, FOS, TGFBR2, and ITK and up-regulation of MPO, TPX2, and TYMS in drug-treated CML cases relative to normal samples led to the up-regulation of cell cycle, DNA replication, and DNA repair pathways and down-regulation of immune system, chemokine and interleukin signaling, TCR signaling, TGF beta signaling, and MAPK signaling pathways. Further, significant up-regulation of LAPTM4B, HLTF, PIEZO2, CFH, CD109, ANGPT1 influence autophagy, stem cell, complement system, TGFβ Receptor and homeostasis pathway subsequently leading to resistance in \>1% BCR-ABL copies of CML treated cases.

Hence, we suggest that genes included in these pathways may be used as markers for CML development (FOS, TGFBR2, TPX2) and CML resistance to therapy (LAPTM4B, HLTF, PIEZO2, CFH, CD109, ANGPT1). This dynamic was accompanied by a loss of 7q31.2 (MET) in low CNVs in the undetectable BCR-ABL-TKI-sensitive group and were identified and previously reported as CNVs 9q34.11-q34.2 (FNBP1, ABL1, NUP214, TSC1, RALGDS) in the high CNVs-BCR-ABL-dependent and independent-TKI-non-sensitive groups. Further, rsID239798 (Ch6:54940890) and rsID9475077 (Ch6:54941691) were associated with FAM83B, a proto-oncogene that has previously been implicated in therapeutic resistance to TKI.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s6}
==========================================
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